809 related articles for article (PubMed ID: 16199713)
1. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
Wooditch AC; Aronoff SC
Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
3. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment.
Durongpisitkul K; Gururaj VJ; Park JM; Martin CF
Pediatrics; 1995 Dec; 96(6):1057-61. PubMed ID: 7491221
[TBL] [Abstract][Full Text] [Related]
4. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
Chen S; Dong Y; Yin Y; Krucoff MW
Heart; 2013 Jan; 99(2):76-82. PubMed ID: 22869678
[TBL] [Abstract][Full Text] [Related]
6. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease.
Zhu BH; Lv HT; Sun L; Zhang JM; Cao L; Jia HL; Yan WH; Shen YP
Eur J Pediatr; 2012 Mar; 171(3):571-8. PubMed ID: 22057683
[TBL] [Abstract][Full Text] [Related]
8. Infections and Kawasaki disease: implications for coronary artery outcome.
Benseler SM; McCrindle BW; Silverman ED; Tyrrell PN; Wong J; Yeung RS
Pediatrics; 2005 Dec; 116(6):e760-6. PubMed ID: 16322132
[TBL] [Abstract][Full Text] [Related]
9. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
Chen S; Dong Y; Kiuchi MG; Wang J; Li R; Ling Z; Zhou T; Wang Z; Martinek M; Pürerfellner H; Liu S; Krucoff MW
JAMA Pediatr; 2016 Dec; 170(12):1156-1163. PubMed ID: 27749951
[TBL] [Abstract][Full Text] [Related]
10. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF;
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869
[TBL] [Abstract][Full Text] [Related]
11. The prevention of coronary arterial abnormalities in Kawasaki disease: A meta-analysis of the corticosteroid effectiveness.
Yang TJ; Lin MT; Lu CY; Chen JM; Lee PI; Huang LM; Wu MH; Chang LY
J Microbiol Immunol Infect; 2018 Jun; 51(3):321-331. PubMed ID: 28927685
[TBL] [Abstract][Full Text] [Related]
12. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications.
De Rosa G; Pardeo M; Rigante D
Eur Rev Med Pharmacol Sci; 2007; 11(5):301-8. PubMed ID: 18074939
[TBL] [Abstract][Full Text] [Related]
13. Management of acute and refractory Kawasaki disease.
Tacke CE; Burgner D; Kuipers IM; Kuijpers TW
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1203-15. PubMed ID: 23199405
[TBL] [Abstract][Full Text] [Related]
14. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
[TBL] [Abstract][Full Text] [Related]
15. Kawasaki disease: part II. Complications and treatment.
Bayers S; Shulman ST; Paller AS
J Am Acad Dermatol; 2013 Oct; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
[TBL] [Abstract][Full Text] [Related]
16. Corticosteroid therapy for primary treatment of Kawasaki disease - weight of evidence: a meta-analysis and systematic review of the literature.
Athappan G; Gale S; Ponniah T
Cardiovasc J Afr; 2009; 20(4):233-6. PubMed ID: 19701534
[TBL] [Abstract][Full Text] [Related]
17. [Cardiovascular complications of Kawasaki disease: clinical cases].
Sica F; d'Amato E; Colapietra T; Romondia A
Pediatr Med Chir; 1995; 17(6):531-3. PubMed ID: 8668589
[TBL] [Abstract][Full Text] [Related]
18. Recent developments and controversies in Kawasaki disease.
Guzman-Cottrill JA; Shulman ST
Minerva Pediatr; 2004 Feb; 56(1):51-61. PubMed ID: 15249914
[TBL] [Abstract][Full Text] [Related]
19. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[TBL] [Abstract][Full Text] [Related]
20. [Kawasaki disease: clinical characteristics and cardiovascular involvement in a cohort of 121 patients].
Calabri GB; Falcini F; Favilli S; Pollini I; Capuzzo L; Simonini G; De Simone L
Pediatr Med Chir; 2002; 24(5):352-7; discussion 397-9. PubMed ID: 12494535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
